NEURALPLEXER Trademark Information
Number:
2528124
Words:
NEURALPLEXER
Kind:
Word
Status group:
PENDING
Status code:
Accepted
Status detail:
Awaiting publication
Priority date:
21 Jan 2025
Lodgement date:
06 Mar 2025
First report date:
06 Mar 2025
Acceptance date:
06 Mar 2025
Filing date:
06 Mar 2025
Indexing constituents:
NEURALPLEXERClass:
42
Convention details:
Array
Mark categories:
Trademark
Goods and services:
1) Class: 42Description: Drug discovery services; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence for collecting, analyzing, interpreting and reporting data and information in the field of drug design and development; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence and machine learning for molecular docking; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence for biomolecular structure prediction; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence in the field of drug design and development; research and development of new therapeutic targets for others; scientific and medical research; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for collecting, analyzing, interpreting and reporting data and information in the field of drug design and development; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for molecular docking; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for biomolecular structure prediction; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for automated machine learning in the field of drug design and development; advanced product research in the field of artificial intelligence (AI); research and development of pharmaceutical drugs to treat diseases utilizing a proprietary drug discovery platform; medical and scientific research services in the field of machine learning models for biomolecular structure prediction
History and publication details:
1) Date: 2025-03-06
Display name: Early Acceptance Notice correspondence sent
2) Date: 2025-03-06
Display name: Status change to Accepted
3) Date: 2025-03-06
Display name: Awaiting examination
4) Date: 2025-03-06
Display name: Examination expedited
5) Date: 2025-03-06
Display name: IP Right Filed correspondence sent
6) Date: 2025-03-06
Display name: IP Right Filed Published
7) Date: 2025-03-06
Display name: Status change to Published
8) Date: 2025-03-06
Display name: Minimum Filing Requirements Considered
9) Date: 2025-03-06
Display name: Status change to Filed
10) Date: 2025-03-06
Display name: Status change to Received
11) Date: 2025-03-06
Display name: Trade mark representation updated
12) Date: 2025-03-06
Display name: Application Received
Display name: Early Acceptance Notice correspondence sent
2) Date: 2025-03-06
Display name: Status change to Accepted
3) Date: 2025-03-06
Display name: Awaiting examination
4) Date: 2025-03-06
Display name: Examination expedited
5) Date: 2025-03-06
Display name: IP Right Filed correspondence sent
6) Date: 2025-03-06
Display name: IP Right Filed Published
7) Date: 2025-03-06
Display name: Status change to Published
8) Date: 2025-03-06
Display name: Minimum Filing Requirements Considered
9) Date: 2025-03-06
Display name: Status change to Filed
10) Date: 2025-03-06
Display name: Status change to Received
11) Date: 2025-03-06
Display name: Trade mark representation updated
12) Date: 2025-03-06
Display name: Application Received
Owner Information
Owner structured address:
5627 Oberlin Drive, Suite 120, San Diego, California, UNITED STATES OF AMERICA, Postal Code: 92121
Service Information
Address structured address:
GPO Box 3810, Sydney, NSW, AUSTRALIA, Postal Code: 2001